Beyond fragmentation
Jennifer Cannon, president, commercial operations, pharma services, at Thermo Fisher Scientific explores the strategic and financial value of singlepartner drug development models
Pharmaceutical and biotechnology companies face growing pressure to streamline development, shorten timelines and demonstrate value across every stage of clinical development. Yet many continue to rely on a fragmented outsourcing model, working with separate partners for clinical research, manufacturing and clinical supply services. This approach, while common, can introduce inefficiencies and delays, particularly when coordination across vendors breaks down.
New research from the Tufts Center for the Study of Drug Development( CSDD) offers data-driven insight into an alternative clinical development model. The study, which is currently in peer review, assessed the financial and operational impact of aligning chemistry, manufacturing and controls( CMC) activities with clinical trial study design and execution within a single supplier network.
The assessment used a wellestablished valuation model to explore when and where integration delivers the greatest value. The
14